IJSRST196448 | Received 05 August 2019 | Accepted : 25 August 2019 | July-August-2019 [ 6 (4) : 276-287] © 2019 IJSRST | Volume 6 | Issue 4 | Print ISSN: 2395-6011 | Online ISSN: 2395-602X Themed Section: Science and Technology DOI : https://doi.org/10.32628/IJSRST196445 276 Formulation and Evaluation of Transdermal Patches Containing Glimipiride Ningule Ganesh M., Nagoba Shivappa N.*, Shaikh Atiya L., Wadulkar Raghunath D., Deshmukh Aditye Y. Channabasweshwar Pharmacy College, Latur, Maharashtra, India *Corresponding author : Dr. Nagoba Shivappa N. M. Pharm, Ph.D. Associate Professor and Head, Department of Pharmaceutics, Channabasweshwar Pharmacy College, Kava Road, Latur-413512, Dist. Latur. (MS) ABSTRACT The purpose of this research was to develop a matrix-type transdermal therapeutic system containing drug Glimepride with different ratios of hydrophilic and hydrophobic polymeric systems by the solvent evaporation technique. Different concentrations of oleic acid and isopropyle myristate were used to enhance the transdermal permeation of glimipride. Matrix type transdermal patches prepared by using different ratio of Eudragit RS100, HPMC100M, by using solvent evaporation techniques. All the prepared formulation were subjected to evaluation studies i.e., weight variation, thickness, drug content, moisture content, moisture uptake, flatness and in-vitro drug release. The physicochemical compatibility of the drug and the polymers studied by differential scanning calorimetry and infrared spectroscopy suggested absence of any incompatibility. Compatibility study between drug and polymer can be done by FTIR. From the all formulation batch F3 was optimized formula. Shows linear zero order release for 24 hrs with cumulative % drug diffusion of 88.34% from 4cm 2 patches. It is concluded that concentration of polymer (HPMC100M) when increases into primary layer, then In-vitro diffusion rate also increases and concentration of Eudragit Rs100 when increases, the drug diffusion decreases. It provides better controlled drug release for patch. Keywords : Glimepiride, Matrix Type Transdermal Patch, Eudragit RS 100, In-Vitro Permeation Study I. INTRODUCTION Transdermal drug administration generally refers to topical application of agents to healthy intact skin either for localized treatment of tissues underlying the skin or for systemic therapy. For transdermal products the goal of dosage design is to maximize the flux through the skin into the systemic circulation. Transdermal drug delivery has many advantages over the oral route of administration such as improving patient compliance in long term therapy, bypassing first-pass metabolism, sustaining drug delivery, maintaining a constant and prolonged drug level in plasma, minimizing inter- and intra patient variability, and making it possible to interrupt or terminate treatment. Development of a transdermal delivery system for existing drug molecules not only improves the drug’s performance in terms of safety and efficacy but also therapeutic benefit and improves patient compliance. It is defined as self-contained, discrete dosage forms which are also known as “patches”, when patches are applied to the intact skin, deliver the drug through the skin at a controlled rate to the systemic circulation. Transdermal patch is a medicated adhesive patch which is placed directly above the skin to deliver a exact dose of medication through the skin with a predetermined rate of release to reach into the